A Phase 3 interventional study of Pemigatinib and Gemcitabine in Unresectable Cholangiocarcinoma and Metastatic Cholangiocarcinoma, sponsored by Incyte Corporation. Terminated at 215 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pemigatinib in Cholangiocarcinoma — 6 open to participants now, 6 under way, none of them phase 3. pemigatinib · Cholangiocarcinoma.
Among the 13 studies testing pemigatinib in Cholangiocarcinoma, this one is the 2nd largest by enrollment, is the only one that started in 2019, is the only one in phase 3, and was the 3rd registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →6 of the 13 studies testing pemigatinib in Cholangiocarcinoma are open now, in 1 country. Recruiting first, the newest first:
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Mehmet Akce · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Incyte Corporation
Ages 18+
By country, each count listing its studies:
pemigatinib: first FDA approval 2020 (PEMAZYRE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 1
First in 2015; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 34 across the 13 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 5 studies filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing pemigatinib in Cholangiocarcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06728410Mehmet AkceA Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing pemigatinib in Cholangiocarcinoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemigatinib
Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
Drug: Gemcitabine · Drug: Cisplatin
Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
Also known as: INCB054828
Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
Randomized Treatment Period: Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization until the date of disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] and assessed by an Independent Central Review \[ICR\]) or death, whichever occurs first.
Time frame: up to 1422 days
Randomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time
PFS was defined as the time from the date of randomization until the date of disease progression (according to RECIST v1.1 and assessed by an ICR) or death, whichever occurs first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
Time frame: up to 1422 days
Transition Period: PFS
PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause.
Time frame: up to 1496 days
Transition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time
PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
Time frame: up to 1496 days
Randomized Treatment Period: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
Time frame: up to 1422 days
Transition Period: ORR
ORR was defined as the percentage of participants with a best overall response of CR or PR per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
Time frame: up to 1496 days
Randomized Treatment Period: Overall Survival
Overall survival was defined as the time from the date of randomization until death due to any cause.
Time frame: up to 1422 days
Randomized Treatment Period: Kaplan-Meier Estimates of Overall Survival of the Indicated Lengths of Time
Overall survival was defined as the time from the date of randomization until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
Time frame: up to 1422 days
Randomized Treatment Period: Duration of Response (DOR)
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.
Time frame: up to 1422 days
Randomized Treatment Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.
Time frame: up to 1422 days
Transition Period: DOR
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.
Time frame: up to 1496 days
Transition Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.
Time frame: up to 1496 days
Randomized Treatment Period: Disease Control Rate (DCR)
DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
Time frame: up to 1422 days
Transition Period: DCR
DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
Time frame: up to 1496 days
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.
Time frame: up to 1457 days
Number of Participants With Any Treatment-related TEAE
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.
Time frame: up to 1457 days
Transition Period: Number of Participants With Any TEAE
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.
Time frame: up to 1531 days
Transition Period: Number of Participants With Any Treatment-related TEAE
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.
Time frame: up to 1531 days
Randomized Treatment Period: Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-30) Scores at Early Termination
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to 1422 days
Randomized Treatment Period: Change From Baseline (CFB) in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Including 21 Questions Specific to the Biliary System (EORTC QLQ-BIL21) at Early Termination
The EORTC QLQ-BIL21 assessed QoL across 8 scales: eating, jaundice, tiredness, pain, anxiety, treatment side effects, drains, and weight loss. The raw score of each scale is the mean of the item values that contribute to the scale, and the standardized score is a linear transformation of the raw score so that the range is from 0 to 100. A high score for a symptom scale represents a high level of symptomatology/problems. The BIL21 questionnaire was only be administered to participants for whom the questionnaire is validated in that language. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to 1422 days
Randomized Treatment Period: Number of Participants With the Indicated Responses on the European Quality of Life 5 Dimensions (3 Levels) Questionnaire (EQ-5D [3L])
The EQ-5D (3L) is the descriptive system that comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.
Time frame: Baseline; up to 1422 days
| Milestone | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Started | 83 | 84 |
| Completed | 0 | 0 |
| Not completed | 83 | 84 |
| Withdrew: Death | 51 | 20 |
| Withdrew: Study terminated by sponsor | 26 | 9 |
| Withdrew: Withdrawal by subject | 5 | 12 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Physician decision: worsening of clinical condition | 0 | 1 |
| Withdrew: Transitioned to pemigatinib | 0 | 42 |
| Milestone | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Started | 0 | 42 |
| Completed | 0 | 0 |
| Not completed | 0 | 42 |
| Withdrew: Death | 0 | 27 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 11 |
| Withdrew: Withdrawal by subject | 0 | 2 |
PFS was defined as the time from the date of randomization until the date of disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] and assessed by an Independent Central Review \[ICR\]) or death, whichever occurs first.
| months | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Randomized Treatment Period: Progression-free Survival (PFS) | 8.34 (6.51 to 12.22) | 6.80 (6.05 to 8.25) |
PFS was defined as the time from the date of randomization until the date of disease progression (according to RECIST v1.1 and assessed by an ICR) or death, whichever occurs first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
| percent probability | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| 3 months | 90.0 (81.0 to 94.9) | 77.8 (66.3 to 85.7) |
| 6 months | 68.8 (57.1 to 77.9) | 64.3 (51.9 to 74.3) |
| 9 months | 44.6 (32.7 to 55.8) | 26.5 (16.0 to 38.2) |
| 12 months | 39.1 (27.3 to 50.6) | 17.1 (8.6 to 27.9) |
| 24 months | 20.9 (10.8 to 33.2) | 8.5 (2.2 to 20.2) |
| 36 months | 11.6 (3.1 to 26.4) | 8.5 (2.2 to 20.2) |
PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause.
| months | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| Transition Period: PFS | 8.08 (4.44 to 9.89) |
PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
| percent probability | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| 3 months | 87.6 (72.6 to 94.6) |
| 6 months | 62.4 (45.6 to 75.4) |
| 9 months | 39.7 (24.2 to 54.9) |
| 12 months | 12.6 (3.6 to 27.3) |
| 24 months | 4.2 (0.3 to 17.2) |
| 36 months | 0.0 (NA to NA) |
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
| percentage of participants | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Randomized Treatment Period: Objective Response Rate (ORR) | 47.0 (35.93 to 58.26) | 15.5 (8.51 to 25.01) |
ORR was defined as the percentage of participants with a best overall response of CR or PR per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
| percentage of participants | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| Transition Period: ORR | 38.1 (23.57 to 54.36) |
Overall survival was defined as the time from the date of randomization until death due to any cause.
| months | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Randomized Treatment Period: Overall Survival | 24.38 (18.63 to 35.91) | 25.00 (18.66 to 34.20) |
Overall survival was defined as the time from the date of randomization until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.
| percent probability | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| 3 months | 95.2 (87.7 to 98.2) | 100.0 (100.0 to 100.0) |
| 6 months | 89.1 (80.1 to 94.2) | 97.2 (89.4 to 99.3) |
| 9 months | 81.7 (71.4 to 88.5) | 91.7 (82.4 to 96.2) |
| 12 months | 74.2 (63.3 to 82.4) | 84.7 (74.1 to 91.2) |
| 24 months | 51.0 (38.9 to 61.8) | 55.8 (43.0 to 66.7) |
| 36 months | 36.6 (24.9 to 48.3) | 34.1 (22.0 to 46.5) |
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.
| months | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Randomized Treatment Period: Duration of Response (DOR) | 14.19 (8.74 to 24.74) | 6.31 (4.30 to NA) |
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.
| percent probability | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| 3 months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| 6 months | 80.1 (62.8 to 90.0) | 55.0 (23.2 to 78.3) |
| 9 months | 66.3 (47.1 to 79.9) | 45.8 (16.9 to 71.0) |
| 12 months | 50.4 (31.0 to 67.0) | 34.4 (9.2 to 61.9) |
| 24 months | 33.0 (14.0 to 53.6) | NA (NA to NA) |
| 36 months | 24.8 (7.7 to 46.8) | NA (NA to NA) |
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.
| months | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| Transition Period: DOR | 6.21 (4.17 to 12.45) |
DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.
| percent probability | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| 3 months | 100.0 (100.0 to 100.0) |
| 6 months | 61.4 (33.3 to 80.5) |
| 9 months | 29.8 (8.6 to 55.0) |
| 12 months | 29.8 (8.6 to 55.0) |
| 24 months | 0.0 (NA to NA) |
| 36 months | 0.0 (NA to NA) |
DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
| percentage of participants | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Randomized Treatment Period: Disease Control Rate (DCR) | 89.2 (80.41 to 94.92) | 67.9 (56.78 to 77.64) |
DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
| percentage of participants | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| Transition Period: DCR | 83.3 (68.64 to 93.03) |
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.
| Participants | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 83 | 73 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.
| Participants | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Number of Participants With Any Treatment-related TEAE | 80 | 70 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.
| Participants | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| Transition Period: Number of Participants With Any TEAE | 42 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.
| Participants | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|
| Transition Period: Number of Participants With Any Treatment-related TEAE | 41 |
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Baseline, Appetite loss | 17.1 ± 27.56 | 22.4 ± 31.46 |
| CFB at Early Termination, Appetite loss | 10.2 ± 26.71 | -3.7 ± 32.64 |
| Baseline, Constipation | 12.9 ± 18.75 | 14.9 ± 23.42 |
| CFB at Early Termination, Constipation | 11.8 ± 27.06 | 0.9 ± 30.33 |
| Baseline, Cognitive functioning | 86.4 ± 15.16 | 91.2 ± 13.15 |
| CFB at Early Termination, Cognitive functioning | -5.4 ± 18.05 | -1.9 ± 23.14 |
| Baseline, Diarrhea | 11.1 ± 22.36 | 6.5 ± 15.61 |
| CFB at Early Termination, Diarrhea | 0.5 ± 20.46 | 0.9 ± 12.56 |
| Baseline, Dyspnea | 16.9 ± 24.22 | 14.9 ± 21.15 |
| CFB at Early Termination, Dyspnea | 2.2 ± 24.05 | 8.3 ± 26.87 |
| Baseline, Emotional functioning | 75.9 ± 19.21 | 78.2 ± 20.15 |
| CFB at Early Termination, Emotional functioning | -5.6 ± 20.90 | -9.3 ± 19.60 |
| Baseline, Fatigue | 31.0 ± 25.38 | 26.2 ± 22.53 |
| CFB at Early Termination, Fatigue | 6.8 ± 20.94 | 10.6 ± 22.16 |
| Baseline, Financial difficulties | 14.0 ± 24.64 | 20.4 ± 31.76 |
| CFB at Early Termination, Financial difficulties | 8.1 ± 29.37 | 7.4 ± 26.56 |
| Baseline, Global health status/QoL | 66.7 ± 22.82 | 67.5 ± 20.00 |
| CFB at Early Termination, Global health status/QoL | -8.3 ± 20.36 | -6.0 ± 22.85 |
| Baseline, Insomnia | 30.5 ± 31.27 | 24.9 ± 28.63 |
| CFB at Early Termination, Insomnia | -6.5 ± 29.47 | -3.7 ± 23.61 |
| Baseline, Nausea and vomiting | 8.6 ± 16.27 | 11.1 ± 21.94 |
| CFB at Early Termination, Nausea and vomiting | -1.9 ± 18.13 | 1.4 ± 21.91 |
| Baseline, Pain | 24.6 ± 28.56 | 20.1 ± 23.31 |
| CFB at Early Termination, Pain | 6.6 ± 29.07 | 2.3 ± 22.24 |
| Baseline, Physical functioning | 82.3 ± 21.45 | 82.7 ± 19.21 |
| CFB at Early Termination, Physical functioning | -11.6 ± 20.36 | -5.6 ± 22.79 |
| Baseline, Role functioning | 76.7 ± 31.14 | 79.1 ± 24.51 |
| CFB at Early Termination, Role functioning | -18.0 ± 31.26 | -13.0 ± 26.16 |
| Baseline, Social functioning | 77.4 ± 26.00 | 77.4 ± 24.91 |
| CFB at Early termination, Social functioning | -12.4 ± 27.65 | -11.1 ± 21.82 |
The EORTC QLQ-BIL21 assessed QoL across 8 scales: eating, jaundice, tiredness, pain, anxiety, treatment side effects, drains, and weight loss. The raw score of each scale is the mean of the item values that contribute to the scale, and the standardized score is a linear transformation of the raw score so that the range is from 0 to 100. A high score for a symptom scale represents a high level of symptomatology/problems. The BIL21 questionnaire was only be administered to participants for whom the questionnaire is validated in that language. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Baseline, Anxiety | 35.9 ± 24.78 | 36.1 ± 25.83 |
| CFB at Early Termination, Anxiety | 5.7 ± 24.43 | 0.8 ± 18.50 |
| Baseline, Drains | 2.3 ± 10.14 | 2.9 ± 12.92 |
| CFB at Early Termination, Drains | 3.0 ± 17.15 | 7.8 ± 27.24 |
| Baseline, Eating | 14.9 ± 17.34 | 17.5 ± 19.44 |
| CFB at Early Termination, Eating | 12.2 ± 19.68 | 3.9 ± 21.22 |
| Baseline, Jaundice | 5.6 ± 10.40 | 5.6 ± 10.61 |
| CFB at Early Termination, Jaundice | -1.7 ± 9.99 | 1.5 ± 10.67 |
| Baseline, Pain | 22.5 ± 19.97 | 18.8 ± 18.62 |
| CFB at Early Termination, Pain | -7.6 ± 20.31 | 5.9 ± 15.30 |
| Baseline, Treatment side effects | 14.4 ± 25.33 | 13.0 ± 25.53 |
| CFB at Early Termination, Treatment side effects | 30.5 ± 36.56 | 11.5 ± 30.06 |
| Baseline, Tiredness | 34.8 ± 31.09 | 33.7 ± 32.32 |
| CFB at Early Termination, Tiredness | 6.9 ± 26.99 | 4.0 ± 28.87 |
| Baseline, Weight loss | 18.7 ± 25.26 | 21.0 ± 27.81 |
| CFB at Early Termination, Weight loss | 2.9 ± 22.76 | -9.8 ± 33.36 |
The EQ-5D (3L) is the descriptive system that comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.
| Participants | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD |
|---|---|---|
| Baseline, Anxiety/Depression; no problems | 2 | 1 |
| Baseline, Anxiety/Depression; some problems | 60 | 52 |
| Baseline, Anxiety/Depression; extreme problems | 18 | 15 |
| Early Termination, Anxiety/Depression; no problems | 3 | 0 |
| Early Termination, Anxiety/Depression; some problems | 36 | 26 |
| Early Termination, Anxiety/Depression; extreme problems | 24 | 11 |
| Baseline, Mobility; no problems | 2 | 0 |
| Baseline, Mobility; some problems | 74 | 65 |
| Baseline, Mobility; extreme problems | 5 | 3 |
| Early Termination, Mobility; no problems | 1 | 1 |
| Early Termination, Mobility; some problems | 47 | 33 |
| Early Termination, Mobility; extreme problems | 15 | 3 |
| Baseline, Pain/Discomfort; no problems | 5 | 3 |
| Baseline, Pain/Discomfort; some problems | 52 | 43 |
| Baseline, Pain/Discomfort; extreme problems | 23 | 22 |
| Early Termination, Pain/Discomfort; no problems | 6 | 3 |
| Early Termination, Pain/Discomfort; some problems | 28 | 22 |
| Early Termination, Pain/Discomfort; extreme problems | 28 | 12 |
| Baseline, Self-care; no problems | 4 | 3 |
| Baseline, Self-care; some problems | 41 | 36 |
| Baseline, Self-care; extreme problems | 35 | 28 |
| Early Termination; Self-care; no problems | 2 | 0 |
| Early Termination; Self-care; some problems | 42 | 14 |
| Early Termination; Self-care; extreme problems | 19 | 23 |
| Baseline, Usual Activities; no problems | 2 | 1 |
| Baseline, Usual Activities; some problems | 33 | 29 |
| Baseline, Usual Activities; extreme problems | 46 | 38 |
| Early Termination, Usual Activities; no problems | 3 | 2 |
| Early Termination, Usual Activities; some problems | 30 | 17 |
| Early Termination, Usual Activities; extreme problems | 30 | 18 |
Collected over up to approximately 6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Period: Pemigatinib 13.5 mg QD | 51/83 (61.4%) | 23/83 (27.7%) | 83/83 (100%) |
| Randomized Period: Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 | 47/84 (56%) | 17/73 (23.3%) | 72/73 (98.6%) |
| Transition Period: Pemigatinib 13.5 mg QD | 27/42 (64.3%) | 9/42 (21.4%) | 42/42 (100%) |
| Event | Randomized Period: Pemigatinib 13.5 mg QD | Randomized Period: Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 | Transition Period: Pemigatinib 13.5 mg QD |
|---|---|---|---|
| CholangitisHepatobiliary disorders | 1/83 | 2/73 | 2/42 |
| SepsisInfections and infestations | 3/83 | 0/73 | 1/42 |
| Platelet count decreasedInvestigations | 0/83 | 2/73 | 0/42 |
| Jaundice cholestaticHepatobiliary disorders | 2/83 | 0/73 | 0/42 |
| Abdominal painGastrointestinal disorders | 1/83 | 0/73 | 1/42 |
| AnaemiaBlood and lymphatic system disorders | 0/83 | 1/73 | 1/42 |
| AscitesGastrointestinal disorders | 0/83 | 1/73 | 1/42 |
| Back painMusculoskeletal and connective tissue disorders | 0/83 | 1/73 | 1/42 |
| MalaiseGeneral disorders | 0/83 | 1/73 | 1/42 |
| NauseaGastrointestinal disorders | 0/83 | 0/73 | 1/42 |
| Event | Randomized Period: Pemigatinib 13.5 mg QD | Randomized Period: Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 | Transition Period: Pemigatinib 13.5 mg QD |
|---|---|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 68/83 | 2/73 | 37/42 |
| AlopeciaSkin and subcutaneous tissue disorders | 47/83 | 13/73 | 21/42 |
| AnaemiaBlood and lymphatic system disorders | 12/83 | 37/73 | 5/42 |
| NauseaGastrointestinal disorders | 17/83 | 36/73 | 6/42 |
| StomatitisGastrointestinal disorders | 38/83 | 12/73 | 20/42 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 39/83 | 2/73 | 16/42 |
| ConstipationGastrointestinal disorders | 37/83 | 26/73 | 13/42 |
| DiarrhoeaGastrointestinal disorders | 37/83 | 12/73 | 13/42 |
| FatigueGeneral disorders | 17/83 | 31/73 | 10/42 |
| DysgeusiaNervous system disorders | 31/83 | 8/73 | 15/42 |
| Age, Customized(years) | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD | Total |
|---|---|---|---|
| Mean | 59.4 ± 13.05 | 57.2 ± 12.45 | 58.3 ± 12.76 |
| Sex: Female, Male(Participants) | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD | Total |
|---|---|---|---|
| Female | 46 | 51 | 97 |
| Male | 37 | 33 | 70 |
| Race/Ethnicity, Customized(Participants) | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD | Total |
|---|---|---|---|
| White | 60 | 57 | 117 |
| Black or African American | 5 | 3 | 8 |
| Asian | 11 | 17 | 28 |
| Not Reported | 6 | 5 | 11 |
| Captured as "Hispanic" in the Database | 1 | 0 | 1 |
| Asian - Indian | 0 | 1 | 1 |
| Egyptian | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Pemigatinib 13.5 mg QD | Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 7 |
| Not Hispanic or Latino | 66 | 61 | 127 |
| Not Reported | 10 | 14 | 24 |
| Unknown | 2 | 0 | 2 |
| Captured as "Other" in Database | 1 | 6 | 7 |
Showing the first 100 of 215 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Jun 2019 to primary completion in Jul 2025, 73 months.
Results were first posted in Aug 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemigatinib